Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 7daratumumab 3Peripheral Blood Stem Cell Transplantation 3Calcium Dobesilate 3venetoclax 2pomalidomide 2ixazomib 2fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2ethanolamine oleate 1dexamethasone acetate 1carfilzomib 1birtamimab 1belantamab mafodotin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thalidomide 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Phenytoin 1Pentetic Acid 1Methotrexate 1Melphalan 1In Situ Hybridization, Fluorescence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoglobulin Light-chain Amyloidosis × birtamimab × Clear all
NCT01707264 2018-08-28

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Prothena Biosciences Ltd.

Phase 1/2 Completed
69 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡